Scopus BioPharma Inc. SCPS
At closeNov 3, 2026, 4:00 PM EST
- YTD
- 0.00%
- 1 year
- 0.00%
- Market cap
- 16.83K
- EPS (ttm)
- -0.41
- Shares out
- 21.09M
- Forward P/E
- -0.07
- YTD return
- 0.00%
- 1-year return
- 0.00%
- Volume
- 47.08K
- Avg volume
- 3.55K
- Open
- 0.0004
- Previous close
- 0.0004
- Day's range
- 0.0004 – 0.0004
- 52-week range
- 0.0001 – 0.01
- Beta
- 1.16
- Analysts
- Buy
- Price target
- 12.00 (+2999900.0%)
2Y 0.0000 (0.00%)
Key statistics
- Enterprise value
- 1.61M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -6.46M
- Total cash
- 310.82K
- Total debt
- 0
- Return on equity
- 0.00%
- Short % of float
- 0.25%
- 50-day average
- 0.1921
- 200-day average
- 0.354155
Analyst view
Consensus: buy
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 16, 2021 | Benchmark | init | — | Speculative Buy |
About Scopus BioPharma Inc.
Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. The company lead development programs are immuno-oncology gene therapy for the treatment of various cancers. It offers Duet Platform, a CpG signal transducer and activator of transcription 3 (STAT3) inhibitors; and MRI-1867, rationally designed, orally available, dual-action, hybrid, and small molecule that is an inverse agonist of the endocannabinoid system/cannabinoid receptor 1, as well as an inhibitor of inducible nitric oxide synthase. Scopus BioPharma Inc. has strategic partnerships with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem for its lead development and other programs. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- scopusbiopharma.com
News
Contrasting Scopus BioPharma (NASDAQ:SCPS) & MorphoSys (NASDAQ:MOR) 
Scopus BioPharma's Subsidiary — Duet BioTherapeutics — Presents Compelling New Data for a Novel Treatment for Malignant Glioma at 38th Annual Meeting of the Society for Immunotherapy of Cancer 
Scopus BioPharma's Subsidiary — Duet BioTherapeutics — to Present at the 38th Annual Meeting of the Society for Immunotherapy of Cancer 
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session - Stocks That Hit 52-Week Lows On Monday
- Why Avaya Holdings Shares Are Trading Lower By 62%? Here Are 62 Stocks Moving In Friday's Mid-Day Session
Why Adobe Shares Are Trading Higher; Here Are 31 Stocks Moving Premarket 
Why American Eagle Outfitters Shares Climbed Over 18%; Here Are 78 Biggest Movers From Yesterday 
Stocks That Hit 52-Week Lows On Tuesday 
Why Target Shares Are Trading Lower By 14%? Here Are 56 Stocks Moving In Wednesday's Mid-Day Session
Your note
Sign in to keep a note on SCPS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| GIBSON ROBERT J | Officer and Director | Purchase | Feb 24, 2021 | 300 |
| GREENSPAN IRA SCOTT | Officer, Director and Beneficial Owner | Purchase | Aug 26, 2021 | 0 |
| LAMSTEIN JOSHUA R | Chairman of the Board | Purchase | Aug 26, 2021 | 119,997 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Geode Capital Management, LLC | 1.03% | 217,078 | 19.86K | Sep 29, 2022 |
| M&R Capital Management, Inc. | 0.36% | 76,819 | 7.03K | Dec 30, 2022 |
| Renaissance Technologies, LLC | 0.29% | 61,104 | 5.59K | Sep 29, 2022 |
| Tower Research Capital LLC (TRC) | 0.13% | 26,533 | 2.43K | Sep 29, 2022 |
| State Street Corporation | 0.10% | 20,729 | 1.90K | Sep 29, 2022 |
| HRT Financial LP | 0.07% | 14,353 | 1.31K | Sep 29, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.95% | 200,928 | 18.38K | Nov 29, 2022 |
| Fidelity Series Total Market Index Fund | 0.06% | 13,273 | 1.21K | Nov 29, 2022 |